Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

Sponsor

Liu Zi (Other)

Overall Status

Recruiting

CT.gov ID

NCT05051696

Collaborator

(none)

Enrollment

Location

Arm

26.2

Anticipated Duration (Months)

2.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies. And further research the mechanism of oncolytic viruses H101.

Condition or Disease	Intervention/Treatment	Phase
Genital Neoplasms, Female	Drug: H101	N/A

Detailed Description

Patients with recurrent, radiation/chemotherapy-resistant gynecological cancer carry a poor prognosis. H101 is a recombinant human type-5 adenovirus (Ad5), in which the E1B and E3 gene have been deleted. Previous studies have shown that H101 has anticancer activity and safety in some solid tumors, but has little report in gynecological oncology. In this clinical trial, 60 recurrent or refractory gynecological cancer patients will be enrolled. Based on individual conditions, all eligible patients are intra-tumor injected oncolytic viruses H101 within 5 consecutive days combined with or without radiotherapy in sequential, three weeks for a cycle (1-4 cycles totally). Simultaneously, the tumor sample, peripheral blood, and urine specimen were collected on day1 and day5. Local control rate and side effects are recorded respectively.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

60 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

Actual Study Start Date :

Sep 26, 2021

Anticipated Primary Completion Date :

Dec 1, 2022

Anticipated Study Completion Date :

Dec 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Oncorine (H101) with or without radiotherapy The tumor mass was injected with H101 per day for 5 consecutive days, 3 weeks as one treatment cycle, and 1 to 4 cycles according to the condition of the patient, and the patient was treated with or without radiotherapy in sequential. The injection dose of H101 was determined by the tumor volume or maximum tumor diameter:5.0×10^11 virus particles(VP) for if tumor diameter≤5cm; 1×10^12 VP for the tumor diameter between 5cm and 10cm, and 1.5×10^12 VP for the tumor diameter>10cm.	Drug: H101 Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles) Other Names: Radiotherapy

Arm

Intervention/Treatment

Experimental: Oncorine (H101) with or without radiotherapy

The tumor mass was injected with H101 per day for 5 consecutive days, 3 weeks as one treatment cycle, and 1 to 4 cycles according to the condition of the patient, and the patient was treated with or without radiotherapy in sequential. The injection dose of H101 was determined by the tumor volume or maximum tumor diameter:5.0×10^11 virus particles(VP) for if tumor diameter≤5cm; 1×10^12 VP for the tumor diameter between 5cm and 10cm, and 1.5×10^12 VP for the tumor diameter>10cm.

Drug: H101

Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)

Other Names:

Radiotherapy

Outcome Measures

Primary Outcome Measures

Local Control (LC) [3 months]
LC will be measured from the start date of injection until the date of progressive disease

Secondary Outcome Measures

Objective Response Rate (ORR) [1 year after injection]
ORR is the percentage of participants with presence of complete response (CR), partial response (PR). ORR assessment will be based on RECIST 1.1 criteria
Progress free survival (PFS) [12 months]
Progress free survival is defined as the time from first day of injection until the first date of either objective disease progression or death due to any cause
adverse events [At day 3, 7 and 30]
Toxicity were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Written informed consent obtained.
Age ≥ 18 years at the time of study entry.
Histological or Cytologically diagnosed gynecological malignancies.
Failure to prior standard treatment (surgery, chemotherapy, radiotherapy);
Refractory/recurrence/metastasis gynecological cancer
At least one measurable lesion according to the RECIST1.1.
Cooperative Oncology Group-Status (ECOG Status) 0-3.
The last treatment should be over 2 weeks.

Exclusion Criteria:

History or evidence of active autoimmune disease that requires systemic treatment.
Participated in other anti-tumor clinical trials within 4 weeks.
Patients who have a contraindication to similar drugs.
That failure to follow up regularly.